Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Crossover Study to Assess the Bioequivalence of Fezolinetant Following a Single Dose of Fezolinetant (Test Formulation) Compared to a Single Dose of Fezolinetant Phase 3 Formulation (Reference Formulation) in Healthy Female Subjects

NCT04277624 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT04277624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04277624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Crossover Study to Assess the Bioequivalence of Fezolinetant Following a Single Dose of Fezolinetant (Test Formulation) Compared to a Single Dose of Fezolinetant Phase 3 Formulation (Reference Formulation) in Healthy Female Subjects
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 20, 2020
Completion date
February 26, 2021
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers